vs

Side-by-side financial comparison of CBL & ASSOCIATES PROPERTIES INC (CBL) and CareDx, Inc. (CDNA). Click either name above to swap in a different company.

CBL & ASSOCIATES PROPERTIES INC is the larger business by last-quarter revenue ($156.4M vs $117.7M, roughly 1.3× CareDx, Inc.). CBL & ASSOCIATES PROPERTIES INC runs the higher net margin — 31.3% vs 2.4%, a 28.9% gap on every dollar of revenue. On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs 18.8%). Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (12.9% CAGR vs 10.1%).

CBL & Associates Properties, Inc. is an American real estate investment trust that invests in shopping centers and shopping malls, primarily in the Southeastern and Midwestern United States. The company is organized in Delaware with its headquarters in Chattanooga, Tennessee. Its largest market is Chattanooga, Tennessee. The company's name is based on the initials of its founder, Charles B. Lebovitz.

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

CBL vs CDNA — Head-to-Head

Bigger by revenue
CBL
CBL
1.3× larger
CBL
$156.4M
$117.7M
CDNA
Growing faster (revenue YoY)
CDNA
CDNA
+20.2% gap
CDNA
39.0%
18.8%
CBL
Higher net margin
CBL
CBL
28.9% more per $
CBL
31.3%
2.4%
CDNA
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
12.9%
10.1%
CBL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CBL
CBL
CDNA
CDNA
Revenue
$156.4M
$117.7M
Net Profit
$49.0M
$2.8M
Gross Margin
Operating Margin
1.0%
Net Margin
31.3%
2.4%
Revenue YoY
18.8%
39.0%
Net Profit YoY
29.0%
EPS (diluted)
$1.61
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBL
CBL
CDNA
CDNA
Q1 26
$117.7M
Q4 25
$156.4M
$108.4M
Q3 25
$139.3M
$100.1M
Q2 25
$140.9M
$86.7M
Q1 25
$141.8M
$84.7M
Q4 24
$131.7M
$86.6M
Q3 24
$125.1M
$82.9M
Q2 24
$129.7M
$92.3M
Net Profit
CBL
CBL
CDNA
CDNA
Q1 26
$2.8M
Q4 25
$49.0M
$-4.1M
Q3 25
$75.4M
$1.7M
Q2 25
$2.8M
$-8.6M
Q1 25
$8.8M
$-10.4M
Q4 24
$38.0M
$87.7M
Q3 24
$16.2M
$-10.6M
Q2 24
$4.7M
$-4.6M
Operating Margin
CBL
CBL
CDNA
CDNA
Q1 26
1.0%
Q4 25
-5.6%
Q3 25
-0.2%
Q2 25
-12.8%
Q1 25
-15.8%
Q4 24
97.5%
Q3 24
-16.6%
Q2 24
-7.9%
Net Margin
CBL
CBL
CDNA
CDNA
Q1 26
2.4%
Q4 25
31.3%
-3.8%
Q3 25
54.2%
1.7%
Q2 25
2.0%
-9.9%
Q1 25
6.2%
-12.2%
Q4 24
28.8%
101.3%
Q3 24
12.9%
-12.8%
Q2 24
3.7%
-5.0%
EPS (diluted)
CBL
CBL
CDNA
CDNA
Q1 26
$0.05
Q4 25
$1.61
$-0.08
Q3 25
$2.38
$0.03
Q2 25
$0.08
$-0.16
Q1 25
$0.27
$-0.19
Q4 24
$1.22
$1.60
Q3 24
$0.52
$-0.20
Q2 24
$0.14
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBL
CBL
CDNA
CDNA
Cash + ST InvestmentsLiquidity on hand
$42.3M
$77.9M
Total DebtLower is stronger
$2.2B
Stockholders' EquityBook value
$374.9M
Total Assets
$2.7B
$411.1M
Debt / EquityLower = less leverage
5.79×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBL
CBL
CDNA
CDNA
Q1 26
$77.9M
Q4 25
$42.3M
$177.2M
Q3 25
$52.6M
$194.2M
Q2 25
$100.3M
$186.3M
Q1 25
$100.3M
$230.9M
Q4 24
$40.8M
$260.7M
Q3 24
$65.1M
$240.9M
Q2 24
$57.7M
$228.9M
Total Debt
CBL
CBL
CDNA
CDNA
Q1 26
Q4 25
$2.2B
Q3 25
$2.2B
Q2 25
$2.1B
Q1 25
$2.2B
Q4 24
$2.2B
Q3 24
$1.8B
$0
Q2 24
$1.9B
$0
Stockholders' Equity
CBL
CBL
CDNA
CDNA
Q1 26
Q4 25
$374.9M
$303.1M
Q3 25
$351.4M
$311.1M
Q2 25
$289.4M
$327.4M
Q1 25
$295.0M
$379.3M
Q4 24
$323.5M
$378.4M
Q3 24
$308.3M
$273.2M
Q2 24
$308.8M
$264.7M
Total Assets
CBL
CBL
CDNA
CDNA
Q1 26
$411.1M
Q4 25
$2.7B
$413.2M
Q3 25
$2.7B
$432.3M
Q2 25
$2.6B
$444.3M
Q1 25
$2.6B
$489.6M
Q4 24
$2.7B
$491.1M
Q3 24
$2.2B
$477.0M
Q2 24
$2.3B
$466.8M
Debt / Equity
CBL
CBL
CDNA
CDNA
Q1 26
Q4 25
5.79×
Q3 25
6.21×
Q2 25
7.39×
Q1 25
7.29×
Q4 24
6.84×
Q3 24
5.76×
0.00×
Q2 24
6.00×
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBL
CBL
CDNA
CDNA
Operating Cash FlowLast quarter
$249.7M
$4.3M
Free Cash FlowOCF − Capex
$514.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
5.10×
1.54×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBL
CBL
CDNA
CDNA
Q1 26
$4.3M
Q4 25
$249.7M
$21.4M
Q3 25
$69.6M
$37.4M
Q2 25
$68.3M
$9.9M
Q1 25
$31.7M
$-26.6M
Q4 24
$202.2M
$21.9M
Q3 24
$61.1M
$12.5M
Q2 24
$64.2M
$18.9M
Free Cash Flow
CBL
CBL
CDNA
CDNA
Q1 26
$514.0K
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$46.0M
Q2 24
$54.8M
FCF Margin
CBL
CBL
CDNA
CDNA
Q1 26
0.4%
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
36.8%
Q2 24
42.2%
Capex Intensity
CBL
CBL
CDNA
CDNA
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
12.1%
Q2 24
7.3%
Cash Conversion
CBL
CBL
CDNA
CDNA
Q1 26
1.54×
Q4 25
5.10×
Q3 25
0.92×
22.30×
Q2 25
24.74×
Q1 25
3.60×
Q4 24
5.32×
0.25×
Q3 24
3.77×
Q2 24
13.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBL
CBL

Segment breakdown not available.

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

Related Comparisons